Nevro Corp. (NYSE:NVRO) Receives $6.43 Consensus Target Price from Brokerages
Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...
Business Insider9d
Nevro is not issuing FY25 guidance
As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down
NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...
The Victoria Advocate10d
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...
The Bakersfield Californian9d
Nevro: Q4 Earnings Snapshot
The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...